Erasca Inc. (ERAS)
Erasca Inc. (ERAS) Stock Price, Analysis & Data
| Бид | 13.27 |
| Рыночная капитализация | 6.33B |
| Выручка (TTM) | n/a |
| Чистая прибыль (TTM) | -287.22M |
| Бета | 0.65 |
| EPS (TTM) | -0.95 |
| P/E (TTM) | n/a |
| Прогнозный P/E | -31.11 |
| P/B (TTM) | 15.63 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 11, 2026 |
| Аск | 23 |
| Объём торгов | 1,830,092 |
| Ср. объём (20д) | 4,923,824 |
| Открытие | 18.19 |
| Пред. закрытие | 18.28 |
| Диапазон дня | 17.85 - 18.72 |
| Диапазон за 52 недели | 1.33 - 24.28 |
| Аналитики | n/a |
| Целевая цена | n/a |
| Дивиденды | n/a |
| Дата отсечки | n/a |
О компании ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...
Финансовые результаты
В 2025 году выручка Erasca составила 0 — это рост на undefined% к прошлогодним 0. Прибыль составила -124.55M — это снижение на -22.95%.
Финансовая отчётностьСюрприз в отчёте
Аналитики ждут выручку ... Улучшить тариф
1 месяц назад · Simply Wall St.
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On ReturnsErasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...
1 месяц назад · Simply Wall St.
Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...
